Skip to main content


You are viewing the new article page. Let us know what you think. Return to old version

Invited speaker presentation | Open | Published:

Systematic review on treatment of juvenile idiopathic arthritis – associated uveitis


Juvenile idiopathic arthritis (JIA) is commonly complicated by chronic uveitis that frequently leads to visual loss.


Review of the current literature on the treatment of JIA - associated uveitis.


Therapy of JIA-associated uveitis is guided by the severity of inflammation and complications. Topical corticosteroids are generally used as the initial treatment. Severe uveitis is commonly treated with immunosuppressive drugs. Methotrexate is presently the first-choice agent. If uveitis is not responding, another immunosuppressive agent or biological is applied. Currently, adalimumab is the preferred TNF-inhibitor. In refractory disease, other biologicals are used (e.g., rituximab, tocilizumab or abatacept). Ocular corticosteroid injections / - implantations are considered as “rescue therapy”.


Controlled studies are warranted to offer most effective and safe therapy for children with JIA - associated uveitis. Better knowledge of the basic mechanisms underlying the disease and of the molecules that are important for regulating inflammation may help to create new and more specific treatment approaches, and to improve disease monitoring.

Disclosure of interest

None declared.

Author information

Correspondence to Arnd Heiligenhaus.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark


  • Corticosteroid
  • Methotrexate
  • Juvenile Idiopathic Arthritis
  • Uveitis
  • Adalimumab